DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor

J Clin Oncol. 2008 Oct 10;26(29):4843-4. doi: 10.1200/JCO.2008.18.1776. Epub 2008 Sep 8.

Authors

Lynn-Kristin Bracht¹, Patrick Wen, Jeffrey A Meyerhardt, Matthew H Kulke, Jason L Hornick, Mark Redston, Debra Conrad LaFrankie, Peter M Black, Santosh Kesari, Andrew Norden, Jan Drappatz

Affiliation

¹ Center for Neuro-Oncology, Boston, MA, USA.

PMID: 18779600
DOI: 10.1200/JCO.2008.18.1776

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use*
Brain Neoplasms / metabolism
Brain Neoplasms / therapy*
Combined Modality Therapy
DNA Repair Enzymes / biosynthesis*
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Disease Progression
Fatal Outcome
Glioblastoma / complications
Glioblastoma / metabolism
Glioblastoma / therapy*
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Male
Middle Aged
Neuroendocrine Tumors / complications
Neuroendocrine Tumors / drug therapy*
Pancreatic Neoplasms / complications
Pancreatic Neoplasms / drug therapy*
Remission Induction
Temozolomide

Substances

Antineoplastic Agents, Alkylating
Dacarbazine
DNA Repair Enzymes
Temozolomide